Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Alzheimer's Disease

    Boston, MA

    Search
    Alzheimer's Disease
    Boston, MA
    Show Map
    Map View
    Boston, MA
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      98 Alzheimer's Disease Trials near Boston, MA

      Power is an online platform that helps thousands of Alzheimer's Disease patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Sensory Stimulation for Alzheimer's Disease

      Newton, Massachusetts
      This is an open-label extension for a multicenter, randomized, double-blind, sham-controlled, adaptive design pivotal study. Participants who complete the Hope Study (CA-0011) will be eligible to consent for screening to enroll in the OLE Hope Study (CA-0015). All participants will be treated with an Active Sensory Stimulation System (GS120) for 60 minutes daily for up to 12 months. There will be no Sham treatment group or randomization involved in this study.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased
      Age:50 - 92

      Key Eligibility Criteria

      Disqualifiers:Insufficient Adherence, Continuous Care, Others
      Must Not Be Taking:Immunomodulators, Memantine, Nootropics

      402 Participants Needed

      Long-Term Safety of Simufilam for Alzheimer's Disease

      Waltham, Massachusetts
      The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RETHINK-ALZ or REFOCUS-ALZ Phase 3 clinical trials.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Age:51 - 89

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      1081 Participants Needed

      THC-Based Medication for Agitation in Alzheimer's

      Amherst, New York
      This trial tests a natural THC-based medicine called IGC-AD1, given in small doses regularly. It targets people aged 60 and above with Alzheimer's-related dementia who have been experiencing agitation. The THC in the medicine helps reduce agitation by interacting with brain signals. The most recent trial reported significant improvement in agitation using nabilone.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:60+

      Key Eligibility Criteria

      Disqualifiers:Seizures, Schizophrenia, Bipolar, Uncontrolled Hypertension, Others

      164 Participants Needed

      The BRAIN App for Dementia

      Winchester, Massachusetts
      There are currently 6.7 million Americans living with dementia and, without significant breakthroughs, this figure will double to 12.7 million by 2050. There are about 46,000 long-term care (LTC) facilities in the U.S. More than half of LTC residents have some form of dementia (Alzheimer's Association, 2018). Responsive behaviors and dysfunction of the dementia care triad-i.e., the PLWD, professional Care Partner (CP), and Family Member (FM)-are inexorably linked. The emergence of responsive behaviors can lead to disruption of the triad's function. Thus, it is imperative to maintain positive relationships and a high quality of life (QoL) within the triad to reduce BPSD. Cognitive Stimulation Therapy (CST) has demonstrated improvements in QoL and relationships for PLWD. CST is a psychosocial intervention that promotes communication and engagement in PLWD via a structured program of meaningful and enjoyable theme. While clinical trials have shown improvement in cognition and QoL, the potential large-scale impact of CST has been hampered by low adherence, with less than 40% completing trials. One likely reason for the low adherence to CST is the reliance on generic and non-digital tools (e.g., paper-based agendas, tools, DVDs, and board games) in facilitating the intervention. That is, even though CST aims to be personalized, the specific interventions used in the field tend to be generic and not tailored to each PLWD's specific interests. The use of digital technology to implement CST would offer considerable advantages to expand and personalize the range of stimulation content and provide a means for monitoring responses, optimizing protocols, and promoting adherence. The proposed Phase II study will involve the continued development and evaluation of a multi-faceted software platform called "Building Relationships using Artificial Intelligence and Nostalgia" or BRAIN. The BRAIN Platform will be the first-ever Artificial Intelligence (AI) powered CST digital therapy platform for PLWD. The platform, which has been shown to be effective in an initial Phase I clinical trial, has three main goals: to improve the quality of life of PLWD, to reduce BPSD in PLWD, and to foster positive relationships between members of the care triad. The proposed Phase II project has the following Specific Aims: 1. Create an improved Beta version of the BRAIN Platform's eight components: (1) the Admin Management Dashboard, (2) the Annotation Dashboard, (3) the Log Viewer, (4) the Content Management System (CMS), (5) the Private CMS, (6) the Control App, (7) the Home App, and (8) the Training Dashboard. 2. Fine-tune the different classes of AI algorithms-i.e., behavioral analytics, personalized content recommendation, and personalized program generation-in the BRAIN app such that they can (a) recognize and track 12 distinct behaviors and indicators of PLWD, (b) use these behavioral traits as a basis for automatically rating the relative success of each activity, and (c) automatically recommend personalized activities that are likely to be successful for individual PLWD. 3. Conduct a Cluster Randomized Trial (CRT) of the BRAIN App to examine the app's impact on engagement/affect, quality of life, and responsive behaviors. 4. Examine satisfaction and ease of use of the app for PLWD, LTC staff, and FMs.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:65+

      Key Eligibility Criteria

      Disqualifiers:Non-verbal, Visual/hearing Impairments, Others

      120 Participants Needed

      Music Therapy for Dementia

      Winchester, Massachusetts
      Healthcare systems around the world, including within the United States, have long-established shortages of trained caregivers. The American Health Care Association states that "the health care system has experienced a shortage of trained caregivers for critical roles for some time." This scarcity directly impacts the 45,800 Long-Term Care (LTC) communities throughout the U.S. Concurrent with this staff shortage, more than half of LTC residents have some form of dementia. These two issues create a serious public health concern, since dementia is associated with a variety of behavioral expressions, such as aggression, anxiety, and agitation. Behavioral expressions of dementia can be successfully managed with the use of tailored, psychosocial interventions and communication support. Unfortunately, existing staff shortages make the facilitation of such interventions challenging. One powerful and often-overlooked approach to ameliorating staffing shortages involves the utilization of retired volunteers to facilitate interventions for persons with dementia (PWD). Based on the nearly universal love of music and a promising pilot study, the product to be developed and tested in this STTR will build upon the combined prior work of the Principal Investigators. Making Connections Thru Music (MCTM), an urgently needed product, will enable retired volunteers to facilitate an evidence-based music and discussion intervention with PWD. MCTM aims to improve engagement, enhance quality of life, and reduce behavioral expressions in PWD. The intervention will consist of two main components: (1) a comprehensive online training course for volunteers, which will provide a general overview of dementia, demonstrate effective communication strategies to use with PWD, and instruct volunteers to effectively facilitate MCTM sessions, and (2) an app containing a structured MCTM intervention protocol and toolkit, which will be the means by which volunteers facilitate MCTM. MCTM will be marketed to LTC communities.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Dementia, Cognitive Impairment, Rapid Decline

      196 Participants Needed

      Nicotinamide Riboside for Alzheimer's Disease

      Belmont, Massachusetts
      This trial is testing nicotinamide riboside (NR), a form of vitamin B3, to see if it can help people with early memory problems or mild Alzheimer's. The idea is that NR can boost a molecule called NAD+ in the brain, which helps cells produce energy and reduces stress. Researchers hope this will improve brain function in these patients. Nicotinamide riboside (NR) is a precursor to NAD+ and has shown potential in improving learning and memory in animal models of dementia.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Early Phase 1
      Age:55 - 89

      Key Eligibility Criteria

      Disqualifiers:Psychotic Disorder, Stroke, Cancer, Others
      Must Not Be Taking:Benzodiazepines, Barbiturates, Opiates, Others

      50 Participants Needed

      Allopregnanolone for Alzheimer's Disease

      Waltham, Massachusetts
      A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:55 - 80

      Key Eligibility Criteria

      Disqualifiers:Stroke, Seizure Disorder, Malignant Disease, Others
      Must Not Be Taking:Benzodiazepines, Anticonvulsants, Antipsychotics, Others

      200 Participants Needed

      Donanemab for Early Alzheimer's Disease

      Watertown, Massachusetts
      This trial is testing different doses of donanemab, a drug aimed at helping people with early Alzheimer's disease. Donanemab has shown rapid reduction of brain amyloid in early Alzheimer's disease. The study will look at how often and how severely participants experience a side effect involving brain swelling. Researchers also want to find out which patient characteristics might predict this side effect.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:60 - 85

      Key Eligibility Criteria

      Disqualifiers:Neurological Disease, Serious Illnesses, Cancer, Others
      Must Not Be Taking:Anti-amyloid Immunotherapy

      1175 Participants Needed

      Care Coordination Program for Dementia

      Watertown, Massachusetts
      This is a randomized, pragmatic clinical trial to evaluate the effectiveness of a collaborative care-coordination program embedded in a health plan for people living with Alzheimer's disease and related dementias (ADRD) and their care partners versus usual care. The study population will include community-dwelling Medicare Advantage members living with ADRD and their care partners. Outcomes will be healthcare utilization outcomes of individuals with ADRD and include emergency department visits, outpatient visits, avoidable emergency department visits, and admission to long-term care facilities.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Nursing Home, Hospice, Dementia Care Program

      2160 Participants Needed

      Escitalopram for Agitation in Alzheimer's Disease

      Quincy, Massachusetts
      The purpose of this study is to evaluate the safety and efficacy of escitalopram for agitation in Alzheimer's dementia.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      187 Participants Needed

      ECT for Dementia

      Belmont, Massachusetts
      This study will explore the effect of ECT treatments plus usual care (ECT+UC) in reducing severe agitation in patients with moderate to severe dementia including Alzheimer's Disease, Vascular dementia, Frontotemporal dementia, and Dementia with Lewy Bodies. The study will also determine the tolerability/safety outcomes of ECT+UC.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:40+

      Key Eligibility Criteria

      Disqualifiers:Delirium, Stroke, Schizophrenia, Bipolar, Others

      50 Participants Needed

      AVP-786 for Agitation in Alzheimer's Disease

      Braintree, Massachusetts
      This trial is testing a medication called AVP-786 on individuals who have taken part in previous studies. The goal is to see if this medication can help with their conditions over time.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Age:50 - 90

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      1197 Participants Needed

      Buntanetap for Alzheimer's Disease

      Foxborough, Massachusetts
      The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are: * Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13? * Does buntanetap/Posiphen improve function as measured by ADCS-iADL? * What medical issues do participants have, if any, when taking buntanetap/Posiphen? Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease. Participants will: * Take buntanetap/Posiphen or a placebo every day for 18 months * Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18 * Complete pre- and post-clinic visit phone calls
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:55 - 85

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Bipolar, Major Depression, Others
      Must Be Taking:Cholinesterase Inhibitors, Memantine

      760 Participants Needed

      Semaglutide for Early Alzheimer's Disease

      Methuen, Massachusetts
      This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance. The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits participants will have blood samples taken. Participants must have a study partner, who is willing to take part in the study. Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period. A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study will be performed on a selection of sites based on their experience with CSF sampling and willingness to participate in this sub-study. The endpoints related to this sub-study are exploratory only.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:55 - 85

      Key Eligibility Criteria

      Disqualifiers:Parkinson's, Schizophrenia, Bipolar, Others
      Must Be Taking:Alzheimer's Treatments

      1840 Participants Needed

      VHB937 for Alzheimer's Disease

      Methuen, Massachusetts
      This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension. The double-blind part is 72 weeks long, followed by an extension.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:50 - 85

      Key Eligibility Criteria

      Disqualifiers:Non-AD Dementia, Cardiac Conditions, Stroke, Cancer, Others
      Must Be Taking:AChEIs, Memantine

      407 Participants Needed

      Mevidalen for Alzheimer's Disease

      Methuen, Massachusetts
      The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:50 - 80

      Key Eligibility Criteria

      Disqualifiers:Childbearing Potential, CNS Disease, Others
      Must Not Be Taking:CYP3A4 Inhibitors, Inducers

      300 Participants Needed

      Semaglutide for Early Alzheimer's Disease

      Methuen, Massachusetts
      This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance. The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits participants will have blood samples taken. Participants must have a study partner, who is willing to take part in the study. Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period. A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study will be performed on a selection of sites based on their experience with CSF sampling and willingness to participate in this sub-study. The endpoints related to this sub-study are exploratory only.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:55 - 85

      Key Eligibility Criteria

      Disqualifiers:Parkinson's, Schizophrenia, Bipolar, Others
      Must Be Taking:Alzheimer's Treatments

      1840 Participants Needed

      ALZ-801 for Early Alzheimer's Disease

      Plymouth, Massachusetts
      This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is an open-label trial of treatment with ALZ-801.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:50 - 85

      Key Eligibility Criteria

      Disqualifiers:Moderate-severe ARIA, Others
      Must Not Be Taking:Amyloid Antibodies

      163 Participants Needed

      PMN310 for Alzheimer's Disease

      Plymouth, Massachusetts
      This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions of PMN310 in patients with early Alzheimer's disease.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:50+

      Key Eligibility Criteria

      Disqualifiers:Parkinson's, Huntington's, Stroke, Others
      Must Be Taking:Acetylcholinesterase Inhibitors, Memantine

      128 Participants Needed

      Nicotine Patch for Mild Cognitive Impairment

      Plymouth, Massachusetts
      The purpose of the study is to see if daily transdermal nicotine is able to produce a significant cognitive, clinical and functional improvement in participants with MCI. Neuronal nicotinic receptors have long been known to play a critical role in memory function in preclinical studies, with nicotine improving attention, learning, and memory function. The study will enroll 380 participants for a 2 year period. Participants will be randomized (50:50) to either the transdermal nicotine, beginning at 7mg/day, and increasing to 21mg/day, or placebo skin patch.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Tobacco Use, Neurologic Disease, Major Depression, Others
      Must Be Taking:Memantine, Cholinesterase Inhibitors

      380 Participants Needed

      Why Other Patients Applied

      "I watched my mother suffer through years of Alzheimer's Disease and I want to help advance the science for treating AD. I don't want anyone else to have go through what our family went through."

      OF
      Alzheimer's Disease PatientAge: 65

      "I'm so used to losing things, forgetting things, making up to acronyms to remember things only to remember the acromym but not what the letters stand for... I enter a new room to look for an item, only to forget what I was looking for. I've discussed the existing treatments with my neurologist and she's on board with my joining a clinical trial."

      AH
      Dementia PatientAge: 64

      "I have been on standard Alzheimer's medication for a few years but know this treatment only works to delay my cognitive deterioration, not improve it. I've been doing research, which brought me here, to consider some of the latest research drugs. While I know that there's no guarantee that a clinical trial improves my condition, I'd like to give one a try and help further the research for all."

      VL
      Alzheimer's PatientAge: 71

      "I have a very strong family history of Alzheimer’s, with my maternal grandmother, mother, uncle, and sister having the disease. My APOE status is 2/4. My memory is going, although 6 months ago I tested decently on some cognitive tests. I'd like to help myself by getting ahead of my condition and help others in a similar situation by participating in medical research."

      EK
      Mild Cognitive Impairment PatientAge: 72

      "I watched my mother die from Parkinson’s. At the time of her death, she weighed 85 pounds and could not move any muscles voluntarily except her eyelids. I would like to participate in a trial to help find a better treatment for PD than what is currently available. It is a devastating illness. It breaks my heart that other families will have to go through this."

      WU
      Healthy Volunteer PatientAge: 76
      Match to a Alzheimer's Disease Trial

      Piromelatine for Alzheimer's Disease

      Island Park, Rhode Island
      This trial tests piromelatine, a pill taken before bed, in people with mild Alzheimer's who lack a specific genetic variation. The goal is to see if it can improve brain function and slow down dementia progression.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2, 3
      Age:60 - 85

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Bipolar, Cardiovascular, Others
      Must Be Taking:Acetylcholinesterase Inhibitors, Memantine

      225 Participants Needed

      KarXT + KarX-EC for Agitation in Alzheimer's Disease

      Worcester, Massachusetts
      The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Schizophrenia, Urinary Retention, Others
      Must Not Be Taking:MAO Inhibitors, Anticonvulsants, Mood Stabilizers, Tricyclics

      352 Participants Needed

      KarXT + KarX-EC for Alzheimer's Disease

      Worcester, Massachusetts
      The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 3
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular, Pulmonary, Renal, Others

      600 Participants Needed

      Xanamem for Alzheimer's Disease

      East Providence, Rhode Island
      Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD). This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:50+

      Key Eligibility Criteria

      Disqualifiers:Non-AD Dementia, Major Mental Illness, Diabetes, Others
      Must Be Taking:Symptomatic AD Medications

      220 Participants Needed

      BMS-986368 for Alzheimer's Disease

      East Providence, Rhode Island
      This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Schizophrenia, Schizoaffective, Others

      120 Participants Needed

      JNJ-64042056 for Alzheimer's Disease

      Providence, Rhode Island
      The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:55 - 75

      Key Eligibility Criteria

      Disqualifiers:Alzheimer's Dementia, Mild Cognitive Impairment, Others

      498 Participants Needed

      ABBV-916 for Early Alzheimer's Disease

      Providence, Rhode Island
      This trial is testing a new drug called ABBV-916 to see if it can help people aged 50-90 who are in the early stages of Alzheimer's disease. Participants will receive the drug regularly over several months. The study aims to find out if the drug is safe and effective by monitoring changes in symptoms and side effects.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:50 - 90

      Key Eligibility Criteria

      Disqualifiers:Vasogenic Edema, Microhemorrhages, Others
      Must Not Be Taking:Anticoagulants

      106 Participants Needed

      Emtricitabine for Alzheimer's Disease

      Providence, Rhode Island
      This is a randomized, double-blind clinical trial of a daily oral dose of 200 mg emtricitabine vs. placebo in 35 participants with biomarker-confirmed MCI or mild to moderate dementia due to Alzheimer's disease. Study duration for each subject participating in the placebo-controlled research study will be approximately 12 months (up to a 3 months Screening Period, Baseline visit (1 month), 6 months of placebo or emtricitabine dosing, and 1 month follow-up). Participants will have up to 2 months to complete all procedures for the month 6 study visit.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:50 - 85

      Key Eligibility Criteria

      Disqualifiers:Parkinson's, Schizophrenia, Bipolar, Others
      Must Be Taking:Cholinesterase Inhibitors, Memantine

      35 Participants Needed

      Educational Program for Alzheimer's Disease

      Worcester, Massachusetts
      Potentially inappropriate prescribing includes the use of medications that may no longer be necessary or that may increase the risk of harm. Inappropriate prescribing can increase the overall symptom burden, and negatively affect health-related quality of life and function. The inappropriate prescription of certain drug categories such as sedative/hypnotics, antipsychotics, and strong anticholinergic agents poses particular risks for older adults, and may be more common among those with Alzheimer's disease and Alzheimer's disease- related dementias (AD/ADRD) due to a higher prevalence of multimorbidity and more frequent prescription of five or more medications. The D-PRESCRIBE-AD (Developing a PRogram to Educate and Sensitize Caregivers to Reduce the Inappropriate Prescription Burden in Elderly with Alzheimer's Disease) study will test a health plan-based intervention using the NIH Collaboratory's Distributed Research Network, which employs the Food and Drug Administration (FDA) Sentinel System infrastructure. The overarching goal of this randomized controlled trial is to assess the effect of a patient/caregiver- centered, multifaceted educational intervention on potentially inappropriate prescribing in patients with AD/ADRD. The research hypothesis is that education on inappropriate prescribing among patients/caregivers and their providers can reduce medication-related morbidity in patients with AD/ADRD and improve medication safety for this vulnerable population. The study population will include community-dwelling patients with AD/ADRD, identified based on diagnoses codes of AD/ADRD or use of a medication for Alzheimer's Disease, who have evidence of potentially inappropriate prescribing the three drug classes above. The trial will evaluate the effect of mailed educational interventions, including the effect of a second reminder mailing, designed to spur patient/caregiver-provider communication about medication safety (versus usual care) on the proportion of patients with inappropriate prescribing, the primary outcome of this study. The trial will be conducted in two large, national health plans.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:50+

      Key Eligibility Criteria

      Disqualifiers:Nursing Home, Palliative Care, Others
      Must Be Taking:Alzheimer's Medications

      11375 Participants Needed

      Health Education for Alzheimer's Disease Prevention

      Providence, Rhode Island
      Modifying health behaviors like physical activity level, diet, stress, and mental activity level can lower risk for Alzheimer's disease, but many middle-aged and older adults find it difficult to sustain health behavior changes over the long term. This project will develop a new intervention that educates people about Alzheimer's disease risk factors and helps them understand how their personal health beliefs may prevent them from making long-lasting lifestyle changes. The goal is to help people sustain health behavior changes to prevent or delay the onset of Alzheimer's disease and related dementias.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Age:45 - 69

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      40 Participants Needed

      1234

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Alzheimer's Disease clinical trials in Boston, MA pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Alzheimer's Disease clinical trials in Boston, MA work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Alzheimer's Disease trials in Boston, MA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Boston, MA for Alzheimer's Disease is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Boston, MA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Alzheimer's Disease medical study in Boston, MA?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Alzheimer's Disease clinical trials in Boston, MA?

      Most recently, we added NPC1 for Alzheimer's Disease, Dementia Care Training for Dementia and KarXT + KarX-EC for Alzheimer's Disease to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in Massachusetts

      Anxiety Clinical Trials in Massachusetts

      Schizophrenia Clinical Trials in Massachusetts

      ADHD Clinical Trials in Massachusetts

      Bipolar Disorder Clinical Trials in Massachusetts

      Multiple Sclerosis Clinical Trials in Massachusetts

      Autism Clinical Trials in Massachusetts

      Treatment Resistant Depression Clinical Trials in Massachusetts

      Borderline Personality Disorder Clinical Trials in Massachusetts

      Social Anxiety Disorder Clinical Trials in Massachusetts

      Parkinson's Disease Clinical Trials in Massachusetts

      Alzheimer's Disease Clinical Trials in Massachusetts

      By Location

      Clinical Trials near Boston, MA

      Clinical Trials near Worcester, MA

      Clinical Trials near Springfield, MA

      Clinical Trials near Burlington, MA

      Clinical Trials near Fall River, MA

      Clinical Trials near Cambridge, MA

      Clinical Trials near North Dartmouth, MA

      Clinical Trials near Newton, MA

      Clinical Trials near Waltham, MA

      Clinical Trials near Watertown, MA

      Clinical Trials near Belmont, MA

      Clinical Trials near Brockton, MA

      Other People Viewed

      By Subject

      32 Alzheimer's Disease Trials near Columbia, SC

      91 Parkinson's Disease Trials near Boston, MA

      59 Alzheimer's Disease Trials near Phoenix, AZ

      83 Alzheimer's Disease Trials near San Antonio, TX

      77 Alzheimer's Disease Trials near Los Angeles, CA

      76 Alzheimer's Disease Trials near Anaheim, CA

      27 Alzheimer's Disease Trials near Cincinnati, OH

      43 Alzheimer's Disease Trials near Austin, TX

      18 Celiac Disease Trials near Miami, FL

      Top Depression Clinical Trials near Boston, MA

      Top Breast Cancer Clinical Trials near Boston, MA

      Top Alzheimer's Disease Clinical Trials near Houston, TX

      By Trial

      Brain Stimulation for Alzheimer's Disease

      Light Therapy for Alzheimer's Disease

      Ketogenic Diet vs Low-Fat Diet for Alzheimer's Disease

      Exergames for Mild Cognitive Impairment

      Sleep + Cognitive Training for Cognitive Impairment

      Mind-Body Training for Mild Cognitive Impairment

      Brain Stimulation for Dementia and Memory Loss

      Tau PET Imaging for Metabolic Health

      School Readiness Program for Sickle Cell Disease

      Intensive Blood Pressure Management for Dementia

      AV-1451 Imaging for Apraxia of Speech

      PlanYourLifespan.org for Cognitive Impairment

      Related Searches

      Top Alzheimers-disease Clinical Trials near Anaheim, CA

      Top Clinical Trials near Missouri

      Top Alzheimers-disease Clinical Trials near High Point, NC

      Top Alzheimers-disease Clinical Trials near Albuquerque, NM

      Top Alzheimers-disease Clinical Trials near Austin, TX

      Top Alzheimers-disease Clinical Trials near San Antonio, TX

      Top Alzheimers-disease Clinical Trials near Glendale, AZ

      Cross-Education Strength Training for Post-Meniscus Surgery Recovery

      Zanzalintinib for Thyroid Cancer

      Evorpacept + Cetuximab + Pembrolizumab for Colorectal Cancer

      MK-7684A + Chemotherapy for Lung Cancer

      Overheard Speech Learning for Autism